Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/226496
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

AuthorsMateos, Maria Victoria; Kumar, S. ; Dimopoulos, Meletios A.; González-Calle, Verónica; Kastritis, Efstathios; Hajek, Roman; Fernández de Larrea, Carlos; Morgan, Gareth J.; Merlini, Giampolo; Goldschmidt, Hartmut; Geraldes, Catarina; Gozzetti, Alessandro; Kyriakou, Charalampia; Garderet, Laurent; Hansson, Markus; Zamagni, Elena; Fantl, Dorotea; Leleu, Xavier; Kim, Byung-Su; Esteves, Graça; Ludwig, Heinz; Usmani, Saad Z.; Min, Chang-Ki; Qi, Ming; Ukropec, Jon; Weiss, Brendan M.; Rajkumar, S. Vincent; Durie, B.; San-Miguel, Jesús
KeywordsCancer epidemiology
Myeloma
Issue Date2020
PublisherSpringer Nature
CitationBlood Cancer Journal 10: 102 (2020)
AbstractSmoldering multiple myeloma (SMM) is an asymptomatic precursor state of multiple myeloma (MM). Recently, MM was redefined to include biomarkers predicting a high risk of progression from SMM, thus necessitating a redefinition of SMM and its risk stratification. We assembled a large cohort of SMM patients meeting the revised IMWG criteria to develop a new risk stratification system. We included 1996 patients, and using stepwise selection and multivariable analysis, we identified three independent factors predicting progression risk at 2 years: serum M-protein >2 g/dL (HR: 2.1), involved to uninvolved free light-chain ratio >20 (HR: 2.7), and marrow plasma cell infiltration >20% (HR: 2.4). This translates into 3 categories with increasing 2-year progression risk: 6% for low risk (38%; no risk factors, HR: 1); 18% for intermediate risk (33%; 1 factor; HR: 3.0), and 44% for high risk (29%; 2–3 factors). Addition of cytogenetic abnormalities (t(4;14), t(14;16), +1q, and/or del13q) allowed separation into 4 groups (low risk with 0, low intermediate risk with 1, intermediate risk with 2, and high risk with ≥3 risk factors) with 6, 23, 46, and 63% risk of progression in 2 years, respectively. The 2/20/20 risk stratification model can be easily implemented to identify high-risk SMM for clinical research and routine practice and will be widely applicable.
Description© The Author(s) 2020.
Publisher version (URL)http://dx.doi.org/10.1038/s41408-020-00366-3
URIhttp://hdl.handle.net/10261/226496
DOI10.1038/s41408-020-00366-3
E-ISSN2044-5385
Appears in Collections:(IBMCC) Artículos

Files in This Item:
File Description SizeFormat
International_Mateos_Art2020.pdf835,96 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

PubMed Central
Citations

18
checked on Jan 28, 2022

SCOPUSTM   
Citations

34
checked on Jan 22, 2022

WEB OF SCIENCETM
Citations

31
checked on Jan 23, 2022

Page view(s)

106
checked on Jan 28, 2022

Download(s)

73
checked on Jan 28, 2022

Google ScholarTM

Check

Altmetric

Dimensions


Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.